The Annual Cost of Defecation Disorders

Published Online: Tuesday, July 10, 2012
Follow Pharmacy_Times:
Fecal incontinence—the inability to control the passage of stool— is an expensive problem that can cost more than $4000 per person per year, according to a new study published in Diseases of the Colon & Rectum. The prevalence of fecal incontinence is expected to increase substantially as the elderly population continues to grow rapidly.

Investigators, led by senior author Dee E. Fenner, MD, Harold A. Furlong Professor of Women’s Health and codirector of the Michigan Bowel Control Program, calculated the hidden cost of complex defecation disorders. They examined 3 categories of expenses: direct medical cost (diagnosis, treatment and management of the condition), direct nonmedical cost (costs of nonmedical resources like protective products or transportation to care), and indirect cost, measured by loss of productivity.

Dr. Fenner concluded that because of its social stigma, too little attention is devoted to the treatment and prevention of fecal incontinence. In fact, this is the first US-based study to determine the condition’s per-patient cost.

“The disease is prevalent among men and women, and this study shows the cost is a significant burden to patients and to society,” she said.

To read more articles in this watch, click:
Flying Increases Risk of IBD Flares
T
he Annual Cost of Defecation Disorders


Related Articles
Cancer treatment is more closely involving community and specialty pharmacies, as many patients are being treated with oral, subcutaneous, and intravenous (IV) agents in the comfort of their own homes.
Health-system pharmacists can play a pivotal role in ensuring medication adherence among anticoagulated patients during transitions of care.
The FDA has granted breakthrough therapy designation to Genzyme’s olipudase alfa enzyme replacement treatment for nonneurological manifestations of acid sphingomyelinase deficiency.
Four separate drug manufacturers have launched generic versions of Shire’s Intuniv ADHD treatment for children aged 6 to 17 years.
Latest Issues
$auto_registration$